Roivant Sciences (ROIV) traded higher as investors continued to price in a major balance-sheet catalyst announced in early March: a $2.25 billion global settlement between Genevant Sciences (a Roivant subsidiary) and Arbutus Biopharma with Moderna tied to lipid nanoparticle (LNP) patent litigation. The agreement calls for a $950 million upfront payment in July 2026, with a further $1.3 billion contingent on a separate appellate ruling, providing a clear near-term cash inflow that can support development spending and capital returns.

Alongside the settlement update, Roivant’s board authorized an increase in the company’s common share repurchase program to up to $1.0 billion (inclusive of the previously announced $500 million authorization). With the settlement’s non-contingent cash proceeds expected in July 2026, the expanded buyback capacity is being viewed as more actionable, potentially supporting the share price through reduced float and signaling confidence in intrinsic value.

Key swing factors from here include (1) confirmation and timing around receipt of the $950 million payment in July 2026, (2) developments in the appellate process that determine whether the additional $1.3 billion becomes payable, and (3) the pace and method of repurchases under the $1.0 billion authorization. Separately, pipeline and regulatory updates remain an additional driver for sentiment as Roivant investors weigh trial progress and potential approvals against ongoing R&D cash burn.